[
  {
    "ts": "2025-05-21T14:10:08+00:00",
    "headline": "Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed",
    "summary": "Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive air",
    "url": "https://finance.yahoo.com/news/morgan-stanley-sees-modest-earnings-141008102.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "aec42d8b-1849-3993-9492-cb23db64e13d",
      "content": {
        "id": "aec42d8b-1849-3993-9492-cb23db64e13d",
        "contentType": "STORY",
        "title": "Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed",
        "description": "",
        "summary": "Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive air",
        "pubDate": "2025-05-21T14:10:08Z",
        "displayTime": "2025-05-21T14:10:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/morgan-stanley-sees-modest-earnings-impact-to-resmed-from-apnimed",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wQLbgcmg1_LCnonZisQTBg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4qj03S00max5j.Q8euF.Hg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-sees-modest-earnings-141008102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-sees-modest-earnings-141008102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RMD"
            },
            {
              "symbol": "RSMDF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]